<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730180</url>
  </required_header>
  <id_info>
    <org_study_id>60006</org_study_id>
    <nct_id>NCT04730180</nct_id>
  </id_info>
  <brief_title>Comparison of Targeting Methods for Transcranial Magnetic Stimulation Treatment of Depression</brief_title>
  <acronym>XRnav</acronym>
  <official_title>Evaluating the Effectiveness of Different Targeting Approaches for Transcranial Magnetic Stimulation Treatment of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to learn whether use of a mixed reality device for transcranial magnetic stimulation&#xD;
      (TMS) targeting can improve treatment outcomes compared to targeting through scalp&#xD;
      measurements or a commercial neuronavigation system. Prior studies indicate that&#xD;
      neuronavigation can lead to improved treatment outcomes compared to scalp measurements, but&#xD;
      neuronavigation adaption has been lacking due to the increased burden of the neuronavigation&#xD;
      setup on the TMS operator. We will assess whether use of a mixed reality device can decrease&#xD;
      that burden and speed up the neuronavigation process and is feasible to be used in a clinical&#xD;
      setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior studies suggest that treatment efficacy for TMS treatment of depression is affected by&#xD;
      the targeting method used to guide TMS coil placement. We will compare the treatment outcome&#xD;
      for three patient groups. TMS coil placement is guided for group 1) with simple scalp&#xD;
      measurement targeting, for group 2) with a mixed reality neuronavigation system.&#xD;
&#xD;
      The treatment schedule for the medically prescribed TMS treatment for each patient are 30&#xD;
      daily weekday repetitive TMS treatments for 6 weeks with an additional 6 treatments tapered&#xD;
      over 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2024</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with response to TMS</measure>
    <time_frame>9 weeks</time_frame>
    <description>We will count how many participants responded to TMS treatment in each arm. Response is measured as a more than 50% reduction in MADRS score per patient.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>No neuronavigation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed reality neuronavigation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Simulation</intervention_name>
    <description>Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.</description>
    <arm_group_label>Mixed reality neuronavigation</arm_group_label>
    <arm_group_label>No neuronavigation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mixed reality neuronavigation</intervention_name>
    <description>Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.</description>
    <arm_group_label>Mixed reality neuronavigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ages 18-75.&#xD;
&#xD;
          2. MRI scanning eligibility, including no evidence of any form of metal embedded in the&#xD;
             body (e.g., metal wires, nuts, bolts, screws, plates, sutures), as these produce&#xD;
             artifacts when brain imaging. All potential subjects for the MRI component will need&#xD;
             to successfully complete the screening forms at the Stanford Center for Cognitive and&#xD;
             Neurobiological Imaging (CNI) or the Lucas Center. Those subjects who present no&#xD;
             contraindications to being scanned will be allowed to participate.&#xD;
&#xD;
          3. Healthy subjects with no history of any Axis I psychiatric disorder, are taking&#xD;
             psychotropic medication, or use illicit drugs.&#xD;
&#xD;
          4. Clinical subjects with a diagnosis of treatment resistant depression and prescribed a&#xD;
             clinical course of treatment with rTMS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindication to being scanned in the 3.0T scanner at the Lucas Center or CNI&#xD;
             such as having a pacemaker or implanted device that has not been cleared for scanning&#xD;
             at 3.0 Tesla.&#xD;
&#xD;
          2. History of neurological disorders including but not limited to brain surgery, deep&#xD;
             brain stimulation, radiation treatment, brain hemorrhage or tumor, stroke, seizures or&#xD;
             epilepsy, head trauma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer A McNab, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer A McNab, PhD</last_name>
    <phone>(650) 724-1195</phone>
    <email>mcnabj@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Leuze, PhD</last_name>
    <phone>6502509332</phone>
    <email>cleuze@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer A McNab</last_name>
      <phone>650-724-1195</phone>
      <email>mcnabj@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jennifer McNab</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

